DGAP-Adhoc: Resaphene Suisse AG: Annual General Meeting approves capital increase with subscription rights for existing shareholders

Geneva, September 30, 2018 - Resaphene Suisse AG, ISIN CH0367465439, WKN A2JG91, approved a capital increase of CHF 100,000 to CHF 1,100,000 at its Annual General Meeting. All existing shareholders have a subscription right in the amount of their previous investment. The new shares will be issued at CHF 1 each. They are entitled to dividend for the financial year 2018 and have the same rights as the previous shares. The Board of Directors is instructed to carry out the capital increase.

The background to the capital increase is the restructuring of the major shareholder with an investment of currently 25%. The net proceeds of the capital increase will flow to the company.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Roggwil, Switzerland, is a
Medical technology company founded in 2015 and since 2016
under the name tinniwell a tinnitus therapy device distributes. As another
distribution companies are the Resaphene Deutschland GmbH in
Konstanz and the Resaphene UK Ltd. in London.

++ contact for further questions:

Resaphene Suisse AG
Rütistrasse 8b
9325 Roggwil
Switzerland

Investor Relations Contact:
Mr. Thomas Rauterkus (Chief Financial Officer)
t.rauterkus@resaphene.ch